Clovis Expands Portfolio of Targeted Cancer Drugs with EOS Purchase
By Heather Cartwright
Pharma Deals Review: Vol 2013 Issue 12 (Table of Contents)
Published: 2 Dec-2013
DOI: 10.3833/pdr.v2013.i12.1994 ISSN: 1756-7874
Section: Mergers & Acquisitions
Fulltext:
Abstract
Putting its share price gains to good use, Clovis Oncology has acquired the Italian cancer drug developer Ethical Oncology Sciences (EOS) for an upfront consideration of US$200 M, including US$190 M in Clovis common stock and US$10 M in cash...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS